TLRK was featured on CNBC this morning and in this article:
Tularik surges, biotechs slip
By Ted Griffith, CBS.MarketWatch.com
Last Update: 9:52 AM ET Aug. 27, 2002
NEW YORK (CBS.MW) -- Shares of Tularik surged out ahead of other biotechnology stocks in early trading Tuesday after the company said it would move ahead with testing of an experimental cancer treatment.
Shares of Tularik (TLRK: news, chart, profile) jumped 62 cents, or 8 percent, to $8.12. The South San Francisco-based company said it planned to advance its drug, called T67, into late-stage testing on patients with a form of cancer that begins in the liver. Tularik said it made its decision after receiving "feedback" from the U.S. Food and Drug Administration.
The overall biotech sector, meanwhile, headed lower. The Amex Biotechnology Index (BTK: news, chart, profile) shed 1.2 percent and the Nasdaq Biotechnology Index (NBI: news, chart, profile) declined 0.9 percent.
marketwatch.com
[Edit] Here's an additional excerpt from another article:
Tularik (TLRK: news, chart, profile) rose more than 11 percent after the company said that it will move forward with a pivotal phase 2/3 study of T67, its lead anti-cancer drug for the treatment of hepatocellular carcinoma. The company said it received a letter from the Food and Drug Administration regarding its design for the study, and that the feedback in that letter made an end-of-phase 2 meeting scheduled for Tuesday unnecessary. Tularik expects to open the trial early next year.
marketwatch.com |
